Back to Search
Start Over
SARS‐CoV‐2 infection and vaccination in patients with hairy‐cell leukaemia.
- Source :
- British Journal of Haematology; May2023, Vol. 201 Issue 3, p411-416, 6p
- Publication Year :
- 2023
-
Abstract
- Summary: Little is known of the course of COVID‐19 and the antibody response to infection or vaccination in patients with hairy‐cell leukaemia (HCL). Among a total of 58 HCL cases we studied in these regards, 37 unvaccinated patients, mostly enjoying a relatively long period free from anti‐leukaemic treatment, developed COVID‐19 between March 2020 and December 2021 with a usually favourable outcome (fatality rate: 5/37, 14%); however, active leukaemia, older age and more comorbidities were associated with a worse course. Postinfection (n = 11 cases) and postvaccination (n = 28) seroconversion consistently developed, except after recent anti‐CD20 or venetoclax therapy, correlating with perivaccine B‐cell count. Vaccination appeared to protect from severe COVID‐19 in 11 patients with breakthrough infection. [ABSTRACT FROM AUTHOR]
- Subjects :
- COVID-19 pandemic
LEUKEMIA
BREAKTHROUGH infections
SARS-CoV-2
VACCINATION
Subjects
Details
- Language :
- English
- ISSN :
- 00071048
- Volume :
- 201
- Issue :
- 3
- Database :
- Complementary Index
- Journal :
- British Journal of Haematology
- Publication Type :
- Academic Journal
- Accession number :
- 163160991
- Full Text :
- https://doi.org/10.1111/bjh.18606